The Microbiome and Cancer Treatment

Nyhet

Overcoming Resistance and Enhancing Efficacy

Häftad, Engelska, 2026

Av Sadhna Aggarwal, Garima Malik, Arun Kumar Singh, Meenakshi Dhanawat

2 579 kr

Kommande

The Microbiome and Cancer Treatment: Overcoming Resistance and Enhancing Efficacy delves into the intricate relationship between the microbiome and cancer treatment, highlighting the microbiome's critical role in drug resistance and therapeutic efficacy. The chapters are meticulously organized to provide a deep understanding of how the microbiome interacts with the immune system and influences cancer development and response to therapies. This book opens new avenues for investigation by providing a better understanding of the mechanisms of resistance and the role of microbiome alterations in chemoresistance. This knowledge can guide the development of innovative strategies to counteract drug resistance. The book also addresses the complex "chicken-or-egg" relationship between microbiome alterations and chemoresistance. A diverse blend of chapters fosters interdisciplinary collaboration across fields such as immunology, microbiology, oncology, and pharmacology, promoting holistic approaches to cancer treatment. The audience can benefit by gaining awareness and a better understanding of how the microbiome impacts health, particularly in the context of cancer, leading to more informed health choices.

Fosters a comprehensive understanding of the microbiome's role in cancer treatment, encouraging collaboration among researchers and healthcare professionals to develop holistic and innovative therapeutic strategies
Provides practical insights into microbiome-based strategies to overcome chemoresistance, such as the use of probiotics and prebiotics in cancer therapy
Explores how modulating the gut microbiome can enhance the efficacy of immunotherapies, offering actionable knowledge for the development of personalized and more effective cancer treatments

Produktinformation

Utgivningsdatum2026-08-01
Mått191 x 235 x undefined mm
FormatHäftad
SpråkEngelska
Antal sidor380
FörlagElsevier Science
ISBN9780443332067

Tillhör följande kategorier

Onkologi inom Medicin

Dr. Aggarwal is currently senior postdoctoral fellow at the MD Anderson Cancer Center, Texas, USA. She completed Ph.D. from AIIMS, New Delhi under supervision of Prof. S. N. Das. During PhD, wherein she successfully addressed various aspects of local immunopathology in oral squamous cell carcinoma (OSCC). She published dozens of articles and several book chapters. She is an editorial board member of several indexed reputed international journals. Garima Malik has completed her B. Pharmacy from Vaish Institute of Pharmaceutical Education and Research, Rohtak, and an M.Pharmacy from Chandigarh College of Pharmacy, Landran. She has more than 3 years of experience as an Assistant Professor in the Department of Pharmaceutics. Currently, she is working as an Assistant Professor at M.M College of Pharmacy, Maharishi Markandeshwar University, Mullana, Ambala, India. Ms Garima had about 1.5 years of experience as an officer in the Quality control department at Zenacts Pharma Manimajra, Chandigarh. Her M.Pharmacy project focused on the topic of “Preparation and evaluation of Fusidic acid loaded transferosomes amalgamated with gel for the management of burn wound infection. She has published more than 10 publications, including 1 Patent, and 5 book chapters. Her area of interest is nanotechnology, hydrogels, biomaterials, and their application in drug delivery. Arun Kumar Singh has completed M. Pharm (Pharmaceutics) from Galgotias University, Greater Noida, India. Mr. Singh joined as an assistant professor in the Department of Pharmacy, Vivekanand Global University Jaipur Rajasthan 303012. His area of interest is in the area of nano-formulation, blockchain, IoT, machine learning, cancer, artificial intelligence, big data, and neuroscience. He has authored one book with IOP publishing and has published 5 chapters in big data with River Publisher in Denmark. He has also published 20 review papers among which two are in Biochimica et Biophysica Acta (BBA) – Reviews on Cancer. He has published 26 books with various publishers like IOP, Elsevier, CRC PRESS, and Wiley. Dr. Meenakshi Dhanawat is an Associate Professor at the Amity Institute of Pharmacy, Amity University Haryana, with over 18 years of experience in pharmaceutical sciences. She holds a Master’s degree from NIPER Mohali and a Ph.D. from IIT-BHU Varanasi, specializing in medicinal chemistry and CNS drug delivery targeting 5HT1A/2A receptors. Dr. Dhanawat’s research spans synthetic and heterocyclic chemistry, nanotechnology, drug delivery systems, prodrug design, and herbal drug extraction. She has published 75 research articles and reviews, holds 5 patents, authored 6 books, contributed 13 book chapters, and edited 5 books. An active participant in national and international conferences, she has received prestigious grants from AAPS, DBT, and DST, along with the Rajiv Gandhi National Fellowship. Dr. Dhanawat’s work significantly advances pharmaceutical innovation and education, reflecting her commitment to scientific excellence and mentorship

1. Understanding the Microbiome: Microbiome and Immune System Interactions2. The Microbiome: Its Impact on Cancer Development and Therapeutic Responses3. Microbiome Dynamics in Cancer Treatment: Impact of Chemotherapy on the Microbiome4. Microbiome as a Modulator of Immunotherapy: Synergistic Effects of the Microbiome in Immunotherapy5. Microbiome-Based Strategies to Overcome Chemoresistance: Probiotics and Prebiotics in Cancer Therapy6. Modulating gut microbiome in cancer immunotherapy: Harnessing microbes to enhance treatment efficacy7. The Impact of the Microbiome on Resistance to Cancer Treatment with Chemotherapeutic Agents and Immunotherapy8. Cancer pharmacomicrobiomics: targeting microbiota to optimize cancer therapy outcomes9. Gut microbiome in modulating immune checkpoint inhibitors10. Microbiome-based diagnostics and biomarkers: The search for mechanistic connections11. Modulatory effects of gut microbiome in cancer immunotherapy: A novel paradigm for blockade of immune checkpoint inhibitors12. Current challenges and Future Prospects for Microbiome Research in Cancer Treatment